Diagnose

Building useful clinical tools to identify patients and boost their access to better treatment options.

With the digitization of pathology and the potential of machine learning, the wealth of information contained in pathology slides can be leveraged like never before.

Tip arrowTip arrowTip arrow

Challenges

What if we could help clinicians deliver precision medicine to their patients?

Treatment burden

Treatments for cancer can be toxic, invasive and expensive and may not always be necessary or effective

Disease heterogeneity

Cancer is a highly heterogeneous disease, even cancer of one tissue will have many subtypes that each respond to treatments differently

Anatomic pathology is underutilized

Digital Pathology slides hold vast amounts of hidden insights and unlike genomic data, they are routinely generated in the clinical workflow

Treatment burden

Treatments for cancer can be toxic, invasive and expensive and may not always be necessary or effective

Disease heterogeneity

Cancer is a highly heterogeneous disease, even cancer of one tissue will have many subtypes that each respond to treatments differently

Anatomic pathology is underutilized

Digital Pathology slides hold vast amounts of hidden insights and unlike genomic data, they are routinely generated in the clinical workflow

Owkin’s solution

Owkin delivers AI diagnostic tools that integrate seamlessly into the clinical workflow to provide accurate diagnosis at a fraction of the time and cost of existing tests. Our tools give healthcare providers a fuller picture of a patient’s disease subtype, without the need for costly and time consuming genomic sequencing. This means more patients can be screened, making targeted therapies more accessible to more patients at an earlier stage of their disease.

Breast cancer relapse

Detecting MSI-H

Case study

desktop-arrowmobile-arrow

82% sensitivity

70% specificity

Hazard Ratio of 5.25 between high and low risk groups

arrow-mobile

Impact

Impact

arrow-desktop

Impact pathologists and clinicians

Oncologists can accelerate the clinical utility of specific treatments and give the patients the best possible care pathway.

Biopharma

Pharma can increase the statistical power of phase 3 trials by using this tool to select high-value subgroups with the greatest unmet need and that are most likely to benefit from the treatment.

Testimonials

01/01

background-shapes

“Thanks to the solution we now have a better understanding of the underlying mechanism of highly aggressive tumors and the treatment needs for these patients. Identifying very high-risk patients earlier will enable us to adjust the therapeutic strategy for more favorable patient outcomes.”

Professor Fabrice André

Director of Research, Gustave Roussy

Professor Fabrice André